GUARDANT™

ECLIPSE Readout

December 15, 2022

Safe Harbor

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "to," "target," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. All statements other than statements of historical fact could be deemed forward-looking, including statements regarding: ECLIPSE registrational study results that have not yet been reviewed or approved by the U.S. Food and Drug Administration (FDA); any expectations regarding the Company's commercial engine as a force multiplier for research and development initiatives; any projections of market opportunities or any statements regarding expectations for future reimbursement opportunities; statements regarding the Company's long-term expectations, including with respect to oncology, liquid biopsy, and other aspects of the Company's industry; statements about launching planned new products and additional laboratories, including with respect to Guardant Reveal, CGP tissue assay, and laboratories outside the United States; statements about the expected premarket submission to the FDA of the Company's ECLIPSE registrational study; any statements regarding expectations for future regulatory approvals; any statements about historical results that may suggest trends for the Company's business; any statements of the plans, strategies, and objectives of management for future operations and directions; any statements of expectation or belief regarding future events, opportunities to drive future growth, potential markets or market size, or technology developments; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

The forward-looking statements in this presentation are made only as of the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's periodic filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2021, and any current and periodic reports filed thereafter. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company's expectations.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size, penetration and growth and other data about the Company's industry, which involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of the Company's future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk.

In light of the foregoing, investors are urged not to rely on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company.

Positive ECLIPSE Study Results

Paves the way for first potential FDA-approved and Medicare-reimbursed blood test for CRC screening

83%
CRC Sensitivity
(Overall)

90%
Specificity
(Advanced Neoplasia)

90%
Specificity
(Normal Colonoscopy)

13%
AA Detection

CRC: Colorectal Carcinoma; AA: advanced Adenoma, Advanced Neoplasia: CRC and Advanced Adenoma

Study Participants From Diverse Backgrounds and Settings

SITE ENROLLMENT

>200 sites

- Across 34 states
- Every geographic region in the continental U.S.

Conducted in both rural and urban locations

- Community hospitals
- Private practices
- GI clinics
- Academic medical centers



34 states across every geographic region

GUARDANT

ECLIPSE Study: Analyzed Cohort Demographic

Age Group



Gender

Ethnicity



Race



GUARDANT

Total number of subjects: 10,258; randomly selected cohort from 22,877 enrolled subjects as September 30, 2022; Mean age: 60.6; Median age: 60, Numbers may not add to 100% due to rounding

2022 CRC Screening Compliance in the Unites States



GUARDANT

Sources: 1. 2020 US Census, 2. AACR Study, Cancer Prev Res (2020) 13 (5): 443–448, 3. ACS Colorectal Cancer Facts 2020-2022, 4. EXACT Sciences Q2 2022 Earnings

Blood-based CRC Screening Demonstrates Improved Adherence to Screening in a Real-world Setting

shield™

>8k

Orders placed by end of Sep

>90%

Adherence rate for first 8k patients[1]

Industry benchmark

~65%

Adherence rate[2]

cologuard

Patient survey demonstrates preference for blood test over stool and colonoscopy methods

For patients who have had a stool test only: **7 out of 10** would not choose this modality again

Of the patients who have never been screened: **blood test** was preferred almost **5:1 over a stool**

GUARDANT

Sources: 1. Shield LDT Internal Data, 2. last published by Exact Sciences in their earnings presentation Q1 2018

Long-term Adoption of Blood-Based CRC Screening, Boosted by Patient Preference and Multi-Cancer Screening



*Adoption Index: forecasted adoption based on technical performance of the test (Internal Guardant data)

Unlocking a $20B opportunity for CRC screening in 2022 & beyond

Positive ECLIPSE readout

Complete PMA **submission to FDA** expected in **1Q'23**



GUARDANT


GUARDANT™